Demonstrating non-inferiority of bio-fluorescent particle counter (BFPC) technology to traditional active air-sampling methods is essential for implementation. Here's how to approach it.
- The Missing Layer: Why CAR-T Needs AI As Its Connective Tissue
- Building A Self-Driving Lab For LNP Development
- Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
- Addressing The Particulate Challenge In Cell Therapy Products
- Let's Stop Treating Allogeneic Cell Therapy As One Thing
- Allogeneic Cell Therapy Is Still Learning What Biology Will Allow
- Reassessing Nanoparticle Immunotoxicity: From Well-Established To Novel Approaches
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Study: Ensuring Homogeneity In Biopharmaceutical Aliquotation
Tired of manual manipulation risks in biopharmaceuticals? Discover how automated homogenization ensures consistent cell counts and concentration levels, improving patient safety and process reproducibility.
-
A Novel Patient-Derived Colorectal Cancer Organoid Platform
Patient-derived organoids are revolutionizing drug discovery by mimicking tumors and predicting therapeutic efficacy. Discover a scalable bioprocess that enhances reproducibility and cost-effectiveness to pave the way for broader adoption.
-
Collaborative Variability Reduction In Cell Culture Media
Variability reduction programs improve biomanufacturing by controlling raw‑material complexity, optimizing critical attributes, and boosting productivity through data‑driven partnerships.
-
A Journey To Boundless Automation In Life Sciences
Boundless automation reimagines industrial computing through seamless integration of the intelligent field, edge, and cloud, unified by a real-time data fabric that enables digital transformation.
-
High-Sensitivity IVT mRNA Analysis
Quality analysis of in vitro transcribed (IVT) has become an essential part of biotherapeutic workflows. Discover a high-sensitivity kit made for analyzing IVT mRNA quality to advance your research.
-
Ensuring Product Safety And Purity With Mycoplasma And Sterility Testing
Discover how the Applied Biosystems™ MycoSEQ™ Plus system and Applied Biosystems™ SteriSEQ™ Rapid Sterility Testing System can help accelerate your cell therapy manufacturing process.
-
Automation Of 3D Intestinal Organoids Culture
Gain insight into how 3D organoids promise better disease modeling and drug screening and how challenges like assay complexity, reproducibility, and scalability hinder their widespread adoption in drug discovery.
-
Boosting CMC Regulatory Efficiency In Gene Therapy
Ensure your business stays ahead in today’s complex regulatory environment by implementing robust regulatory affairs strategies that streamline compliance and product approvals.
-
Organ-On-A-Chip Technology Unlocks Patient-Derived Precision Medicine
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
ddPCR Workflows For Gene Expression Analysis
RT-ddPCR offers a powerful, flexible approach to precise RNA quantification. Learn how one-step and two-step workflows improve sensitivity and efficiency in your gene expression studies.
NEWSLETTER ARCHIVE
- 07.27.26 -- Building CGT Manufacturing Capacity For The Next Commercial Era
- 07.24.26 -- Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors
- 07.23.26 -- CGT Biotech/CDMO Transparency & Core Capabilities
- 07.22.26 -- Accelerate Your Gene Therapy Pipeline with NGS, AAV Clearance, and Virus Bank Expertise
- 07.22.26 -- Wondering If Your Org Should Purchase R&D Datasets?
- Solving Vector Yield Challenges Starts Long Before Manufacturing
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
- FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
- In Vivo Gene Editing Is Moving From Promise To Proof
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections